Date of Award

8-13-2020

Document Type

Restricted Access Thesis

Degree Name

MS in Physician Assistant Studies (PA)

First Advisor

Skye Peltier MPH, PA-C

Abstract

Background - Ovarian Cancer (OC) is the 5th most common type of cancer and the deadliest gynecologic cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC), is a non-traditional chemotherapy mostly used for intraperitoneal malignant disease, offers a more efficient way of eradicating the disease. The aim of this research is to compare current management of ovarian cancer with HIPEC treatment. Because HIPEC is delivered through a single treatment during cytoreductive surgery (CRS), the side effects should be less invasive to the patient.

Methods - Data was retrieved from clinical trials, meta-analysis, review articles, and were studied and compared. Most of the research analyzed was conducted in Europe. Notable studies include a review of HIPEC timeline, advantages of neoadjuvant therapy, chemotherapy agents, side effect profile, and a quality of Life (QOL).

Results - Although further research is required, the current body of published journals support the efficacy of HIPEC in ovarian cancer. Worldwide, during the last 40 years, research supports that CS and HIPEC improves survival rates of intraperitoneal cancer including OC.

Conclusions - HIPEC has been shown to prolong overall survival rates. It is important to note that the optimal time to conduct HIPEC requires further evaluation. Common chemotherapy drugs such as Paclitaxel seem to be the most common drugs used for the treatment. However there is not solid agreement on adjuvant and neoadjuvant considerations. At this time, recurrent malignancy and secondary cytoreduction surgery (SRC) should be further studied and compared for more consistent results.

Identifier

SC 11.PAS.2020.Orthey.A

Download

Share

COinS